Kestra Medical: Brian Daniel Webster proposes 15K-share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kestra Medical Technologies, Ltd. (KMTS) officer and director Brian Daniel Webster gave notice of a proposed sale of 15,000 common shares, with an aggregate market value of $426,920.72 and an approximate sale date of November 18, 2026. The notice lists July 21, 2026 as the date of plan adoption or instruction if relying on Rule 10b5-1. It also reports prior sales during the past three months, including 51,900 shares sold on August 4, 2026 for gross proceeds of $1,272,585.45.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Performance Stock Issuance financial
equity compensation plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.